Ginkgo Bioworks (DNA) Stock Forecast & Price Target

$8.29

+0.20 (+2.47%)

(As of 01:03 PM ET)

Ginkgo Bioworks - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Reduce

Based on 6 Analyst Ratings

Sell
3

Hold
2

Buy
1

Based on 6 Wall Street analysts who have issued ratings for Ginkgo Bioworks in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 6 analysts, 3 have given a sell rating, 2 have given a hold rating, and 1 has given a buy rating for DNA.

Consensus Price Target

$3.42
-57.74% Downside

According to the 6 analysts' twelve-month price targets for Ginkgo Bioworks, the average price target is $3.42. The highest price target for DNA is $10.00, while the lowest price target for DNA is $0.01. The average price target represents a forecasted downside of -57.74% from the current price of $8.29.

Get the Latest News and Ratings for DNA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Ginkgo Bioworks and its competitors.

DNA Analyst Ratings Over Time

Type	Current Forecast 10/1/23 to 9/30/24	1 Month Ago 9/1/23 to 8/31/24	3 Months Ago 7/3/23 to 7/2/24	1 Year Ago 10/1/22 to 10/1/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	1 Buy rating(s)	1 Buy rating(s)	2 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)
Sell	3 Sell rating(s)	3 Sell rating(s)	3 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$3.42	$1.43	$0.04	$0.09
Forecasted Upside	-57.74% Downside	-78.57% Downside	N/A	N/A
Consensus Rating	Reduce	Reduce	Reduce	Hold

⭕ [URGENT] Buy Alert just triggered (Ad)

My absolute favorite stock just hit a critical "buy now" trigger price.

Click here for the ticker >>>

DNA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

DNA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Ginkgo Bioworks Stock vs. The Competition

Type	Ginkgo Bioworks	Medical Companies	S&P 500
Consensus Rating Score	1.67	2.78	2.50
Consensus Rating	Reduce	Moderate Buy	Hold
Predicted Upside	-57.10% Downside	2,836.46% Upside	6.35% Upside
News Sentiment Rating	Neutral News See Recent DNA News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/20/2024	TD Cowen 4 of 5 stars		Boost Target	Buy ➝ Buy	$3.00 ➝ $10.00	+26.90%
8/23/2024	BTIG Research 2 of 5 stars	M. Massaro Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Sell ➝ Sell	$0.20 ➝ $7.00	-17.84%
7/9/2024	The Goldman Sachs Group 2 of 5 stars		Lower Target	Sell ➝ Sell	$0.02 ➝ $0.01	-6.65%
5/15/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$0.05 ➝ $0.03	+25.13%
5/10/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Larew Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform ➝ Underperform
11/14/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform	$0.09 ➝ $0.06	+94.52%
11/28/2022	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$0.15	+226.04%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 01:32 PM ET.

DNA Forecast - Frequently Asked Questions

: According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Ginkgo Bioworks is $3.42, with a high forecast of $10.00 and a low forecast of $0.01.
: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ginkgo Bioworks in the last year. There are currently 3 sell ratings, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" DNA shares.
: According to analysts, Ginkgo Bioworks's stock has a predicted downside of -58.76% based on their 12-month stock forecasts.
: Ginkgo Bioworks has been rated by research analysts at BTIG Research, TD Cowen, and The Goldman Sachs Group in the past 90 days.
: Analysts like Ginkgo Bioworks less than other "medical" companies. The consensus rating for Ginkgo Bioworks is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how DNA compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

Buffett Dumps $982 Million in BofA Stock—What Does He Know? (Ad)

Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.

Get your FREE, no-obligation Wealth Protection Guide now

This page (NYSE:DNA) was last updated on 9/30/2024 by MarketBeat.com Staff

From Our Partners